The all-oral combination comprised of revumenib (Revuforj) plus decitabine/cedazuridine and venetoclax (Venclexta; SAVE regimen) elicited responses in patients with newly diagnosed acute myeloid leukemia (AML) although a concern for…
Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML
